Cancer Vaccines Are Hot. The Real Money Might Be in Diagnostics.
Moderna and Merck's personalized cancer vaccines added $50 billion in market value. Now analysts see a $600 million opportunity for Tempus AI in the tumor sequencing behind every dose.
Personalized cancer vaccines aren't just a medical breakthrough anymore. They're becoming a market narrative that's hard to ignore. Moderna and Merck have added more than $50 billion in combined market value on the strength of their melanoma vaccine program, and that's got investors hunting for the next angle. The obvious plays are the drugmakers themselves. The less obvious one might be the diagnostics work sitting underneath every single dose.
Here's the thing: these vaccines don't work without sequencing. Each dose is personalized, which means doctors need to identify the specific mutations in a patient's tumor before the immune system can be trained to attack it. That's not a side detail. That's the foundation. And it's why analyst interest is starting to shift toward companies that own the data and the sequencing infrastructure, not just the vaccine IP.
Tempus AI is the name getting attention now. The company has been building exactly this kind of precision medicine data platform, and analysts see a potential $600 million revenue opportunity tied to the cancer vaccine push. That's a real number, not a rounding error. Granted, Tempus has a history of bold promises and thin margins, so I'm not entirely convinced the market will reward it the way the bulls expect. But the underlying thesis makes sense: if personalized vaccines become standard care, somebody has to do the sequencing at scale.
What's interesting is how this reframes the investment story. The vaccine itself is the headline, but the real recurring revenue might live in the diagnostic work that happens before every treatment. That's a different business model with different economics. It's less flashy, but it could be more durable.
The question worth asking: can Tempus actually convert its data platform into that kind of revenue, or is this another AI story that looks better on paper than in the financial statements? Time will tell, though the next few earnings calls should give us a clearer picture.
